Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 240-249

  Sugawara, Waka ^a,b   Haruta, Masayuki ^a   Sasaki, Fumiaki ^c   Watanabe, Naoki ^a   Tsunematsu, Yukiko ^d   Kikuta, Atsushi ^e   Kaneko, Yasuhiko ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

catenin mutation; Aberrant promoter methylation; Hepatoblastoma; Methylation specific PCR; MSP; RASSF1A; SFRPs

Indexed keywords

BETA CATENIN; DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SULFATE;

ADOLESCENT; ADVANCED CANCER; AGE; ARTICLE; CANCER STAGING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENETIC MARKER; HEPATOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; METHYLATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RASSF1A GENE; SFRP GENE; TREATMENT OUTCOME;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BETA CATENIN; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA, NEOPLASM; EYE PROTEINS; FEMALE; GENE SILENCING; HEPATOBLASTOMA; HUMANS; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; MALE; MEMBRANE PROTEINS; MULTIVARIATE ANALYSIS; MUTATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 34547729171     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21031     Document Type: Article

References (33)

1. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000;1:94-100.
2. Fuchs J, Rydzynski J, Von Schweinitz D et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;95:172-182.
3. Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr 2005;146:204-211.
4. Weber RG, Pietsch T, von Schweinitz D, et al. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000;157:571-578.
5. Kumon K, Kobayashi H, Namiki T, et al. Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: Cytogenetic and comparative genomic hybridization analysis. Jpn J Cancer Res 2001;92:854-862.
6. Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic evaluation of a large series of hepatoblastomas: Numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 2005;44:177-184.
7. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269-273.
8. Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 2001;7:901-908.
9. Koch A, Weber N, Waha A, et al. Mutations and elevated transcriptional activity of conductin (AX1N2) in hepatoblastomas. J Pathol 2004;204:546-554.
10. Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005;11:4295-4304.
11. Wirths O, Waha A, Weggen S, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest 2003;83:429-434.
12. Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989;64:1082-1095.
13. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-3508.
14. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-4349.
15. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-2368.
16. INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-6125.
17. Yang Q, Zage P, Kagan D, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004;10:8493-8500.
18. Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 2002;37:851-856.
19. The Japanese Society of Pathology. Committee on histological classification of childhood tumors. Histological classification and atlas of tumors in infancy and childhood. IV Tumors of the liver, gallbladder and pancreas. 1st Ed Kanahara Shuppan. 1998.
20. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
21. Spugnardi M, Tommasi S, Dammann R, et al. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-1643.
22. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-422.
23. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319.
24. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
25. Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;164:1371-1378.
26. Yang B, House MG, Guo M, et al. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005;18:412-420.
27. Maruyama R, Sugio K, Yoshino I, et al. Hypermethylation of FH1T as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004;100:1472-1477.
28. Koul S, McKiernan JM, Narayan G, et al. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer 2004;3:16.
29. Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004;191:1552-1572.
30. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-1790.
31. Oda H, Imai Y, Nakatsuru Y, et al. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res 1996;56:3320-3323.
32. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann syndrome registry. J Pediatr 1998;132:398-400.
33. Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: A trend or a chance? J Pediatr 1997;130:557-560.